Unexpected therapeutic effects of cisplatin

J 2019

Unexpected therapeutic effects of cisplatin

RAUDENSKÁ, Martina; Jan BALVAN; Michaela FOJTŮ; Jaromír GUMULEC; Michal MASAŘÍK et al.

Základní údaje

Originální název

Unexpected therapeutic effects of cisplatin

Autoři

RAUDENSKÁ, Martina ; Jan BALVAN; Michaela FOJTŮ; Jaromír GUMULEC a Michal MASAŘÍK

Vydání

Metallomics, Cambridge, ROYAL SOC CHEMISTRY, 2019, 1756-5901

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10608 Biochemistry and molecular biology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.796

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/19:00107805

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

VALOSIN-CONTAINING PROTEIN; SENSITIVE CHLORIDE CHANNELS; ENDOPLASMIC-RETICULUM STRESS; ANTICANCER DRUG CISPLATIN; COPPER TRANSPORTER CTR1; TUMOR-NECROSIS-FACTOR; NONMUSCLE MYOSIN IIA; BREAST-CANCER CELLS; MHC CLASS-I; INTRACELLULAR PH

Štítky

14110515, 14110518, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 22. 11. 2019 13:47, Mgr. Tereza Miškechová

Anotace

V originále

Cisplatin is a widely used chemotherapeutic agent that is clinically approved to fight both carcinomas and sarcomas. It has relatively high efficiency in treating ovarian cancers and metastatic testicular cancers. It is generally accepted that the major mechanism of cisplatin anti-cancer action is DNA damage. However, cisplatin is also effective in metastatic cancers and should, therefore, affect slow-cycling cancer stem cells in some way. In this review, we focused on the alternative effects of cisplatin that can support a good therapeutic response. First, attention was paid to the effects of cisplatin at the cellular level such as changes in intracellular pH and cellular mechanical properties. Alternative cellular targets of cisplatin, and the effects of cisplatin on cancer cell metabolism and ER stress were also discussed. Furthermore, the impacts of cisplatin on the tumor microenvironment and in the whole organism context were reviewed. In this review, we try to reveal possible causes of the unexpected effectiveness of this anti-cancer drug.

Návaznosti

GA18-03978S, projekt VaV

Název: Efekt buněčné tuhosti a mikroprostředí jako prediktor odpovědi na léčbu karcinomů hlavy a krku

Investor: Grantová agentura ČR, Efekt buněčné tuhosti a mikroprostředí jako prediktor odpovědi na léčbu karcinomů hlavy a krku

NV18-08-00229, projekt VaV

Název: Interakce buněk nádorového mikroprostředí jako nový nástroj predikce účinnosti terapie nádorů hlavy a krku

Investor: Ministerstvo zdravotnictví ČR, Cell interactions in tumour microenvironment as a new tool for therapy response prediction in head and neck cancer

ROZV/24/LF/2018, interní kód MU

Název: LF - Příspěvek na IP 2108

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, LF - Příspěvek na IP 2108, Interní rozvojové projekty

Citovat

RAUDENSKÁ, Martina; Jan BALVAN; Michaela FOJTŮ; Jaromír GUMULEC a Michal MASAŘÍK. Unexpected therapeutic effects of cisplatin. Metallomics. Cambridge: ROYAL SOC CHEMISTRY, 2019, roč. 11, č. 7, s. 1182-1199. ISSN 1756-5901. Dostupné z: https://doi.org/10.1039/c9mt00049f.

@article{1582296,
   author = {Raudenská, Martina and Balvan, Jan and Fojtů, Michaela and Gumulec, Jaromír and Masařík, Michal},
   article_location = {Cambridge},
   article_number = {7},
   doi = {https://doi.org/10.1039/c9mt00049f},
   keywords = {VALOSIN-CONTAINING PROTEIN; SENSITIVE CHLORIDE CHANNELS; ENDOPLASMIC-RETICULUM STRESS; ANTICANCER DRUG CISPLATIN; COPPER TRANSPORTER CTR1; TUMOR-NECROSIS-FACTOR; NONMUSCLE MYOSIN IIA; BREAST-CANCER CELLS; MHC CLASS-I; INTRACELLULAR PH},
   language = {eng},
   issn = {1756-5901},
   journal = {Metallomics},
   title = {Unexpected therapeutic effects of cisplatin},
   url = {http://dx.doi.org/10.1039/c9mt00049f},
   volume = {11},
   year = {2019}
}

TY  - JOUR
ID  - 1582296
AU  - Raudenská, Martina - Balvan, Jan - Fojtů, Michaela - Gumulec, Jaromír - Masařík, Michal
PY  - 2019
TI  - Unexpected therapeutic effects of cisplatin
JF  - Metallomics
VL  - 11
IS  - 7
SP  - 1182-1199
EP  - 1182-1199
PB  - ROYAL SOC CHEMISTRY
SN  - 17565901
KW  - VALOSIN-CONTAINING PROTEIN
KW  - SENSITIVE CHLORIDE CHANNELS
KW  - ENDOPLASMIC-RETICULUM STRESS
KW  - ANTICANCER DRUG CISPLATIN
KW  - COPPER TRANSPORTER CTR1
KW  - TUMOR-NECROSIS-FACTOR
KW  - NONMUSCLE MYOSIN IIA
KW  - BREAST-CANCER CELLS
KW  - MHC CLASS-I
KW  - INTRACELLULAR PH
UR  - http://dx.doi.org/10.1039/c9mt00049f
L2  - http://dx.doi.org/10.1039/c9mt00049f
N2  - Cisplatin is a widely used chemotherapeutic agent that is clinically approved to fight both carcinomas and sarcomas. It has relatively high efficiency in treating ovarian cancers and metastatic testicular cancers. It is generally accepted that the major mechanism of cisplatin anti-cancer action is DNA damage. However, cisplatin is also effective in metastatic cancers and should, therefore, affect slow-cycling cancer stem cells in some way. In this review, we focused on the alternative effects of cisplatin that can support a good therapeutic response. First, attention was paid to the effects of cisplatin at the cellular level such as changes in intracellular pH and cellular mechanical properties. Alternative cellular targets of cisplatin, and the effects of cisplatin on cancer cell metabolism and ER stress were also discussed. Furthermore, the impacts of cisplatin on the tumor microenvironment and in the whole organism context were reviewed. In this review, we try to reveal possible causes of the unexpected effectiveness of this anti-cancer drug.
ER  -

RAUDENSKÁ, Martina; Jan BALVAN; Michaela FOJTŮ; Jaromír GUMULEC a Michal MASAŘÍK. Unexpected therapeutic effects of cisplatin. \textit{Metallomics}. Cambridge: ROYAL SOC CHEMISTRY, 2019, roč.~11, č.~7, s.~1182-1199. ISSN~1756-5901. Dostupné z: https://doi.org/10.1039/c9mt00049f.

Přehled o publikaci